Novo Nordisk consensus shifts after analyst moves, shares trade lower in Europe

Novo Nordisk sees a marked change in analyst views this week, with Goldman Sachs and Morningstar adjusting their stance and targets while the Danish pharma group’s shares ease on European venues.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 13:01.

Novo Nordisk (DK0060534915) sits at the center of a fresh analyst reassessment this week. On Nasdaq Copenhagen and via its NYSE ADR the Danish pharma group’s shares reflect a marked shift in views from Goldman Sachs and Morningstar, according to recent updates.

What the analysts changed

Goldman Sachs raised its price target for Novo Nordisk to 310 Danish kroner from 305 kroner while reiterating a Neutral rating, as recorded in the Nasdaq Copenhagen quote overview early on June 26. Morningstar followed by downgrading Novo Nordisk from Buy to Hold on June 25, maintaining a target price of 343 Danish kroner, signaling a more cautious stance despite the still-elevated fair value assessment.

German-language analyst flashes earlier in June show Deutsche Bank keeping Novo Nordisk at Hold with a 290-kroner target, positioning the new Goldman level and Morningstar’s 343-kroner figure clearly above this more muted benchmark. The spread between these targets underscores differing views on the sustainability of Novo Nordisk’s high growth in obesity and diabetes treatments, a key point for investors tracking valuation multiples.

Consensus picture going into the weekend

The Nasdaq Copenhagen listing for Novo Nordisk B shares shows a closing price of around 315.65 Danish kroner on June 25, representing a 1.32 percent daily gain on volume above 4.5 million shares. This level sits modestly below Morningstar’s 343-kroner target and slightly above Goldman’s new 310-kroner mark, indicating that the market price currently trades within the analyst target corridor.

On the US side, Novo Nordisk’s ADR on the NYSE under the ticker NVO last closed at 47.55 dollars on June 25, with pre-market indications at 46.89 dollars the following morning, per MarketBeat data. Another real-time source shows the ADR at 47.62 dollars as of the close on June 25, with a market capitalization around 160.17 billion dollars and a trailing P/E of about 11.14, highlighting the scale of the company in the global pharma and obesity-treatment peer group that includes Eli Lilly.

The business behind the stock

Novo Nordisk generates the bulk of its revenue from treatments for diabetes and obesity, most prominently through GLP-1-based drugs such as Ozempic for type 2 diabetes and Wegovy for chronic weight management. Recent coverage highlights that the company’s top US executive is advocating for broader insurance coverage of Wegovy purchases, aiming to increase the share of prescriptions funded by health plans.

Where the stock trades today

As of 2026-06-25, 16:00 Eastern, Novo Nordisk’s ADR (NVO) trades on the NYSE at 47.62 dollars, with a market capitalization of roughly 160.17 billion dollars. The primary Novo Nordisk B shares on Nasdaq Copenhagen closed on 2026-06-25 at about 315.65 Danish kroner, according to MarketScreener price data.

Novo Nordisk at a glance

• Company: Novo Nordisk A/S
• ISIN: DK0060534915
• WKN: A3EU6F
• Ticker: NVO (ADR), NOVO B (Copenhagen)
• Trading venue: NYSE (ADR), Nasdaq Copenhagen
• Price (as of 2026-06-25, 16:00): 47.62 USD (ADR), 315.65 DKK (Copenhagen)
• Market cap: 160.17 billion USD (as of 2026-06-25)
• Sector / industry: Pharmaceuticals / Biotechnology
• Index membership: OMX Copenhagen 25, Stoxx Europe 50, Stoxx Europe 600
• Next earnings date: not officially scheduled

This text is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument. Historical data and analyst opinions are not a guarantee of future performance. Readers should conduct their own research or consult a professional advisor before making investment decisions.